Cell Therapy Pioneers

Cell Therapy Pioneers

Working to provide potentially curative cell therapies to patients with cancer

Latest News

View All
Feb 23, 2024

Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

Read More
Jan 29, 2024

Gamida Cell Actively Pursuing Strategic Alternatives

Read More
Jan 17, 2024

Gamida Cell to Present at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

Read More
Nov 27, 2023

Gamida Cell to Host Virtual Thought Leader Fireside Chat on December 4, 2023

Read More
Nov 20, 2023

Gamida Cell to Present Corporate Highlights at the Piper Sandler 35th Annual Healthcare Conference

Read More
Nov 14, 2023

Gamida Cell Reports Third Quarter 2023 Financial Results and Provides Company Update

Read More
Nov 04, 2023

Gamida Cell Presents New Data on Allogeneic Stem Cell Therapy Omidubicel and Natural Killer (NK) Cell Therapy Candidate GDA-201 at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Read More
Nov 01, 2023

Gamida Cell to Report Third Quarter 2023 Financial Results

Read More
Oct 16, 2023

Gamida Cell Reports Preliminary Data from Phase 1 Study of Natural Killer (NK) Cell Therapy Candidate GDA-201

Read More
Oct 09, 2023

Gamida Cell Issues Update on Israel Operations

Read More
Oct 07, 2023

Gamida Cell Statement Regarding Attacks on Israel

Read More
Oct 02, 2023

Gamida Cell to Present Corporate Highlights at 2023 Cell & Gene Meeting on the Mesa

Read More
Sep 28, 2023

Gamida Cell to Present at Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Read More
Sep 27, 2023

First Patient Receives Gamida Cell's Omisirge™ (omidubicel-onlv)

Read More
Aug 31, 2023

Gamida Cell to Present Corporate Highlights at the H.C. Wainwright 25th Annual Global Investment Conference

Read More
Aug 14, 2023

Gamida Cell Reports Second Quarter and First Half 2023 Financial Results and Provides Company Update

Read More
Aug 01, 2023

Gamida Cell to Report Second Quarter 2023 Financial Results

Read More
Jul 11, 2023

Data Published in Transplantation and Cellular Therapy Suggest Antiviral Protection After Transplantation with Gamida Cell’s Omisirge® (omidubicel-onlv)

Read More
Jun 14, 2023

Gamida Cell To Host Investor Day

Read More
May 31, 2023

Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference

Read More
May 31, 2023

Data To Be Presented on Gamida Cell Natural Killer (NK) Cell Therapy Candidate GDA-201 at the International Society for Cell & Gene Therapy 2023 Annual Meeting

Read More
May 22, 2023

Gamida Cell Appoints Terry Coelho as CFO

Read More
May 15, 2023

Gamida Cell Reports First Quarter 2023 Financial Results and Provides Company Update

Read More
May 11, 2023

Gamida Cell Announces the Date of Its First Quarter 2023 Financial Results and Webcast

Read More
Apr 19, 2023

Gamida Cell Announces Pricing of $23 Million Public Offering of Securities

Read More
Apr 18, 2023

Gamida Cell Announces Launch of Public Offering of Securities

Read More
Apr 17, 2023

Gamida Cell’s Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval

Read More
Mar 27, 2023

Gamida Cell Reports Full Year 2022 Financial Results and Provides Company Update

Read More
Mar 20, 2023

Gamida Cell Announces Changes to Board of Directors

Read More
Mar 20, 2023

Gamida Cell Announces the Date of Its Fourth Quarter and Full Year 2022 Financial Results and Webcast

Read More
Mar 07, 2023

Gamida Cell to Present Corporate Highlights at the Oppenheimer 33rd Annual Healthcare Conference

Read More
Feb 18, 2023

Data Presented on Gamida Cell’s Omidubicel, GDA-201 at the 2023 Tandem Meetings of ASTCT and CIBMTR

Read More
Dec 12, 2022

Gamida Cell Announces Closing of $25 Million Financing With Highbridge

Read More
Nov 23, 2022

Gamida Cell to Present Corporate Highlights at Multiple Upcoming Investor Conferences

Read More
Nov 21, 2022

Gamida Cell Provides Regulatory Update on Omidubicel

Read More
Nov 14, 2022

Gamida Cell Reports Third Quarter 2022 Financial Results and Provides Company Update

Read More
Nov 10, 2022

Gamida Cell to Present Corporate Highlights at the Jefferies London Healthcare Conference

Read More
Nov 07, 2022

Gamida Cell Announces the Date of Its Third Quarter 2022 Financial Results and Webcast

Read More
Nov 07, 2022

GDA-501, NAM enabled NK Cell Therapy, Demonstrates Promising Antitumor Activity Against HER2+ Cancers

Read More
Nov 03, 2022

Gamida Cell Announces Omidubicel Data To Be Presented as an Oral Presentation at 64th ASH Annual Meeting

Read More
Oct 10, 2022

Gamida Cell to Present Corporate Highlights at 2022 Cell & Gene Meeting on the Mesa

Read More
Sep 29, 2022

Long-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers at the Society of Hematologic Oncology Meeting

Read More
Sep 28, 2022

Gamida Cell Announces Entry into Commitment Letter with Highbridge for $25 Million Financing

Read More
Sep 28, 2022

Gamida Cell Announces Pricing of Approximately $20 Million Public Offering of Ordinary Shares

Read More
Sep 27, 2022

Gamida Cell Announces Launch of Public Offering of Ordinary Shares

Read More
Sep 19, 2022

Gamida Cell Appoints Abigail L. Jenkins as President and Chief Executive Officer, Bringing Broad Leadership Experience in Commercializing Innovative Therapies

Read More
Sep 12, 2022

Gamida Cell Presents Data Demonstrating the Impact of Transplantation with Omidubicel for Patients with Hematologic Malignancies at 2022 Cord Blood Connect Meeting

Read More
Aug 15, 2022

Gamida Cell Reports Second Quarter 2022 Financial Results and Provides Company Update

Read More
Aug 10, 2022

Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201

Read More
Aug 08, 2022

Gamida Cell Announces the Date of Its Second Quarter 2022 Financial Results and Webcast

Read More
Aug 01, 2022

Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review

Read More
Jun 13, 2022

Gamida Cell to Present Corporate Highlights at the JMP Securities Life Sciences Conference

Read More
Jun 10, 2022

Gamida Cell Appoints Ivan M. Borrello, M.D., Expert in Immuno-Oncology, Cell Therapies, and Bone Marrow Transplant to Board of Directors

Read More
Jun 02, 2022

Gamida Cell Completes Rolling Biologics License Application Submission to the FDA for Omidubicel

Read More
Jun 01, 2022

Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference

Read More
Jun 01, 2022

Gamida Cell Announces Opening to Enrollment of Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201

Read More
May 17, 2022

Gamida Cell to Present Corporate Highlights at the H.C. Wainwright Global Life Sciences Conference

Read More
May 10, 2022

Gamida Cell Reports First Quarter 2022 Financial Results and Provides Company Update

Read More
May 05, 2022

Gamida Cell Presents New Data from NAM-Enabled Genetically Modified Natural Killer (NK) Pipeline at International Society for Cell & Gene Therapy 2022

Read More
May 03, 2022

Gamida Cell Announces the Date of Its First Quarter 2022 Financial Results and Webcast

Read More
Apr 27, 2022

Gamida Cell Presents Updated One-Year Post-Transplant Follow Up Data from Phase 3 Study of Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings

Read More
Apr 26, 2022

Gamida Cell Announces FDA Clearance of IND and Removal of Clinical Hold for NK Cell Therapy Candidate GDA-201

Read More
Apr 25, 2022

Gamida Cell Presents Updated Omidubicel Data During Best Abstract Award Session at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings

Read More
Apr 25, 2022

Gamida Cell Announces Results of New Health Economic and Outcome Study Reporting Improved Health Equity and Health Outcomes With Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings

Read More
Apr 07, 2022

Gamida Cell to Present Corporate Highlights and Participate in Panel Discussion at the Needham Healthcare Conference

Read More
Mar 15, 2022

Gamida Cell Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update

Read More
Mar 10, 2022

Gamida Cell to Present Corporate Highlights at the Oppenheimer 32nd Annual Healthcare Conference

Read More
Mar 08, 2022

Gamida Cell Announces the Date of Its Fourth Quarter and Full Year 2021 Financial Results and Webcast

Read More
Feb 09, 2022

Gamida Cell Initiates Rolling Submission of Biologics License Application for Omidubicel

Read More
Jan 31, 2022

Gamida Cell Announces Appointment of Anat Cohen-Dayag and Naama Halevi-Davidov to its Board of Directors

Read More
Jan 31, 2022

Gamida Cell Provides Key Program Updates and 2022 Financial Guidance

Read More
Jan 19, 2022

Gamida Cell Provides Update on Omidubicel BLA Submission

Read More
Jan 07, 2022

Gamida Cell Announces Data to be Presented at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings

Read More
Dec 13, 2021

Gamida Cell Presents Two-Year Survival Data for GDA-201 and Resource Utilization Analysis for Omidubicel at 63rd ASH Annual Meeting

Read More
Dec 11, 2021

Gamida Cell Presents New Omidubicel Data at 63rd ASH Annual Meeting

Read More
Nov 16, 2021

Gamida Cell to Present Corporate Highlights at Multiple Upcoming Investor Conferences

Read More
Nov 15, 2021

Gamida Cell Reports Third Quarter 2021 Financial Results and Provides Company Update

Read More
Nov 11, 2021

Gamida Cell Provides Update on Pre-BLA Meeting With FDA for Omidubicel

Read More
Nov 09, 2021

Gamida Cell Presents New Data on Nicotinamide-Enabled NK Cell Therapy at Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting

Read More
Nov 08, 2021

Gamida Cell Announces the Date of Its Third Quarter 2021 Financial Results and Webcast

Read More
Nov 04, 2021

Gamida Cell Announces Data to Be Presented at 63rd ASH Annual Meeting

Read More
Nov 04, 2021

Gamida Cell Presents Data on its NAM-Enabled NK Cell Therapies at Protein & Antibody Engineering Summit (PEGS) Europe

Read More
Oct 26, 2021

Gamida Cell to Present NAM-Enabled, Genetically Modified NK Cell Therapy Pipeline and Update on GDA-201 at Today’s Virtual R&D Day

Read More
Oct 19, 2021

Gamida Cell to Present at Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting

Read More
Sep 28, 2021

Gamida Cell to Host Virtual Event Highlighting GDA-201 and NAM-Enabled, Genetically Modified NK Cell Therapy Pipeline

Read More
Sep 02, 2021

Gamida Cell to Present Corporate Highlights at Multiple Investor Conferences in September

Read More
Aug 11, 2021

Gamida Cell Reports Second Quarter 2021 Financial Results and Provides Company Update

Read More
Aug 04, 2021

Gamida Cell Announces the Date of Its Second Quarter 2021 Financial Results and Webcast

Read More
Aug 03, 2021

Gamida Cell to Present at the BTIG Virtual Biotechnology Conference

Read More
Jun 23, 2021

Gamida Cell Announces Publication in Blood, the Journal of the American Society of Hematology, of the First Pivotal Trial to Evaluate a Cell Therapy (Omidubicel) for Patients with Blood Cancer who Require an Allogeneic Stem Cell Transplant

Read More
Jun 09, 2021

Gamida Cell to Present Corporate Highlights at Multiple Investor Conferences in June

Read More
Jun 07, 2021

Gamida Cell Announces Appointment of Senior Vice President, Global Operations and Manufacturing and Provides Commercial Manufacturing Update

Read More
May 12, 2021

Gamida Cell to Present at the RBC Capital Markets Global Healthcare Conference

Read More
May 11, 2021

Gamida Cell Reports First Quarter 2021 Financial Results and Provides Company Update

Read More
May 04, 2021

Gamida Cell Announces the Date of Its First Quarter 2021 Financial Results and Webcast

Read More
Apr 07, 2021

Gamida Cell to Present at the 20th Annual Needham Virtual Healthcare Conference

Read More
Mar 15, 2021

Gamida Cell Presents Efficacy and Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)

Read More
Mar 09, 2021

Gamida Cell Reports Full Year 2020 Financial Results and Provides Company Update

Read More
Mar 03, 2021

Gamida Cell to Present at Upcoming Investor Conferences

Read More
Mar 02, 2021

Gamida Cell Announces the Date of Its Full Year 2020 Financial Results and Webcast

Read More
Patient focus
Patient focus

We put the needs and experiences of patients at the core of our mission and purpose, working to turn cells into powerful therapeutics.

Future of cancer care
Future of cancer care

Our proprietary nicotinamide (NAM) technology leverages the properties of NAM to enhance and expand cells, creating allogeneic cell therapy products and candidates that are potentially curative for patients with hematologic malignancies.

Dedicated team
Dedicated team

We are pioneers with respected track records in cell therapy research and development, manufacturing and commercialization. We combine bold and creative pursuits in science with a passion for curing cancer so that patients can live longer, better lives.